Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its novel drug SYH2072, a potent aldosterone synthase inhibitor, to conduct clinical trials in the U.S. This product has also been approved by the National Medical Products Administration (NMPA) in China for clinical trials starting in December 2025 [1][1]. Group 1 - The product is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively lowers plasma aldosterone levels without affecting cortisol levels [1][1]. - The approved clinical indications for SYH2072 are uncontrolled hypertension and resistant hypertension [1][1]. - Preclinical studies have shown that the product selectively inhibits aldosterone synthase activity, significantly reducing plasma aldosterone levels in animal disease models and dose-dependently lowering blood pressure in hypertension models, while not affecting cortisol levels [1][1]. Group 2 - The product exhibits favorable pharmacokinetic (PK) characteristics and safety, positioning it as a potential best-in-class drug [1][1]. - The company has submitted multiple patent applications for this product both domestically and internationally [1][1]. - Given the broad clinical demand for aldosterone synthase inhibitors, the product holds significant clinical development value and is expected to provide new treatment options for patients with uncontrolled and resistant hypertension [1][1].

该产品是一种高选择性强效醛固酮合成酶抑制剂(ASI)，可有效降低血浆醛固酮水平，且不影响皮质醇 水平。本次获批的临床适应症为未控制高血压和难治性高血压。临床前研究显示，该产品可选择性抑制 醛固酮合成酶的活性，在动物疾病模型中显著降低血浆醛固酮水平，并剂量依赖性地降低高血压模型的 血压，同时不影响皮质醇水平。该产品具有良好的药代动力学(PK)特性和安全性，使其具备成为一款同 类最优(best-in-class)药物的潜力。目前，集团已在国内外提交了该产品的多项专利申请。 石药集团(01093)发布公告，集团开发的化药1类新药强效醛固酮合成酶抑制剂(SYH2072片)(该产品)已获 得美国食品药品监督管理局批准，可在美国开展临床试验。该产品亦已于2025年12月获得中华人民共和 国国家药品监督管理局批准在中国开展临床试验。 鉴于醛固酮合成酶抑制剂的临床需求广阔，该产品具有较高的临床开发价值，有望为未控制高血压和难 治性高血压患者提供新的治疗选择。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 強效醛固酮合成酶抑制劑（SYH2072片） 在美國獲臨床試驗批准 承董事會命 石藥集團有限公司 主席 蔡東晨 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的化藥1類新藥強效醛固酮合成酶抑制劑（ SYH2072片 ）（「該產品」）已獲得美 國食品藥品監督管理局批准，可在美國開展臨床試驗。該產品亦已於2025年12月獲得中華 人民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該產品是一種高選擇性強效醛固酮合成酶抑制劑(ASI)，可有效降低血漿醛固酮水平，且不 影響皮質醇水平。本次獲批的臨床適應症為未控制高血壓和難治性高血壓 ...

Core Viewpoint - The approval of SYH2072, a novel class I chemical drug developed by the company, by the National Medical Products Administration of China for clinical trials signifies a significant advancement in the treatment of uncontrolled hypertension and primary aldosteronism [1] Group 1: Product Development - SYH2072 is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively lowers plasma aldosterone levels without affecting cortisol levels [1] - The approved clinical indications for SYH2072 include uncontrolled hypertension and primary aldosteronism, addressing a broad clinical need [1] - Preclinical studies demonstrate that SYH2072 selectively inhibits aldosterone synthase activity, significantly reducing plasma aldosterone levels in animal disease models and dose-dependently lowering blood pressure in hypertension models [1] Group 2: Drug Characteristics - The product exhibits favorable pharmacokinetic (PK) properties and safety, positioning it as a potential best-in-class drug [1] - The company has submitted multiple patent applications for SYH2072 both domestically and internationally, indicating a strong commitment to protecting its intellectual property [1] Group 3: Market Potential - Given the extensive clinical demand for aldosterone synthase inhibitors, SYH2072 holds high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary aldosteronism [1]

石药集团(01093)发布公告，集团开发的化药1类新药强效醛固酮合成酶抑制剂(SYH2072片)已获得中华 人民共和国国家药品监督管理局批准，可在中国开展临床试验。 鉴于醛固酮合成酶抑制剂的临床需求广阔，该产品具有较高的临床开发价值，有望为未控制高血压和原 发性醛固酮增多症患者提供新的治疗选择。 该产品是一种高选择性强效醛固酮合成酶抑制剂(ASI)，可有效降低血浆醛固酮水平，且不影响皮质醇 水平。本次获批的临床适应症为未控制高血压和原发性醛固酮增多症。临床前研究显示，该产品可选择 性抑制醛固酮合成酶活性，在动物疾病模型中显著降低血浆醛固酮水平，并剂量依赖性地降低高血压模 型的血压，同时不影响皮质醇水平。该产品具有良好的药代动力学(PK)特性和安全性，使其具备成为一 款同类最优(best-in-class)药物的潜力。目前，集团已在国内外提交了该产品的多项专利申请。 ...

该产品是一种高选择性强效醛固酮合成酶抑制剂(ASI)，可有效降低血浆醛固酮水平，且不影响皮质醇 水平。本次获批的临床适应症为未控制高血压和原发性醛固酮增多症。临床前研究显示，该产品可选择 性抑制醛固酮合成酶活性，在动物疾病模型中显著降低血浆醛固酮水平，并剂量依赖性地降低高血压模 型的血压，同时不影响皮质醇水平。该产品具有良好的药代动力学(PK)特性和安全性，使其具备成为一 款同类最优(best-in-class)药物的潜力。目前，集团已在国内外提交了该产品的多项专利申请。 智通财经APP讯，石药集团(01093)发布公告，集团开发的化药1类新药强效醛固酮合成酶抑制剂( SYH2072片 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。 鉴于醛固酮合成酶抑制剂的临床需求广阔，该产品具有较高的临床开发价值，有望为未控制高血压和原 发性醛固酮增多症患者提供新的治疗选择。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 該產品是一種高選擇性強效醛固酮合成酶抑制劑(ASI)，可有效降低血漿醛固酮水平，且不 影響皮質醇水平。本次獲批的臨床適應症為未控制高血壓和原發性醛固酮增多症。臨床前 研究顯示，該產品可選擇性抑制醛固酮合成酶活性，在動物疾病模型中顯著降低血漿醛固 酮水平，並劑量依賴性地降低高血壓模型的血壓，同時不影響皮質醇水平。該產品具有良 好的藥代動力學(PK)特性和安全性，使其具備成為一款同類最優(best-in-class)藥物的潛力。 目前，本集團已在國內外提交了該產品的多項專利申請。 鑒於醛固酮合成酶抑制劑的臨床需求廣闊，該產品具有較高的臨床開發價值，有望為未控 制高血壓和原發性醛固酮增多症患者提供新的治療選擇。 承董事會命 石藥集團有限公司 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 強效醛 ...

Core Viewpoint - AstraZeneca's stock rose over 2% to $81.99 following positive results from the Baxdrostat clinical trial presented at the 2025 European Society of Cardiology (ESC) annual meeting, indicating significant sales potential in the hypertension treatment market [1] Group 1: Clinical Trial Results - Baxdrostat demonstrated strong efficacy in treating hypertension during the Phase III BaxHTN clinical trial, which could lead to billions in sales opportunities for AstraZeneca [1] - The drug is a highly selective aldosterone synthase inhibitor (ASI) targeting hormones that elevate blood pressure and increase cardiovascular and renal risks [1] Group 2: Market Potential and Approval Timeline - Over 20,000 patients have been enrolled in global clinical trials for Baxdrostat, which includes studies for hypertension, primary aldosteronism, and chronic kidney disease [1] - Baxdrostat is expected to receive regulatory approval in the first half of 2026 in the US and Europe, potentially becoming the first ASI antihypertensive drug on the market [1] Group 3: Analyst Ratings and Price Target - Goldman Sachs has assigned a "Buy" rating to AstraZeneca with a 12-month price target of $99, representing approximately a 23% upside from the stock's closing price of $80.19 [1]

Core Viewpoint - Goldman Sachs recently released a report stating that AstraZeneca (AZN.US) has achieved positive results with Baxdrostat in the Phase III BaxHTN clinical trial, indicating strong potential for hypertension treatment and a multi-billion dollar sales opportunity for the company [1][2]. Group 1: Clinical Trial Results - Baxdrostat demonstrated significant and sustained blood pressure reduction in patients with difficult-to-control hypertension, achieving statistically and clinically meaningful reductions in seated systolic blood pressure (SBP) compared to placebo [2][3]. - The trial results showed that the 2 mg dose of Baxdrostat exhibited long-lasting blood pressure-lowering effects, with nearly three times the rate of patients achieving a systolic pressure of <130 mmHg compared to the placebo group [2][3]. - Overall tolerability of Baxdrostat was good, with no unexpected safety issues reported during the trial [2]. Group 2: Market Potential and Competitive Position - Goldman Sachs has assigned a "Buy" rating to AstraZeneca with a 12-month target price of $99, representing approximately a 23% upside from the stock's closing price of $80.19 [1]. - The Baxdrostat data is expected to generate significant interest among physicians, enhancing its competitive position in the hypertension treatment market [3][4]. - AstraZeneca aims to be the first to market with an aldosterone synthase inhibitor (ASI) antihypertensive drug, with potential approval in the US and Europe expected in the first half of 2026 [3]. Group 3: Future Outlook and Strategic Importance - The strong results from the BaxHTN III trial are seen as a key driver for AstraZeneca's cardiovascular, renal, and metabolic (CVRM) business in the long term [5][6]. - The company is expected to leverage the data to support combination therapy strategies, enhancing market confidence in Baxdrostat's prospects and its potential to contribute to AstraZeneca's goal of reaching $80 billion in revenue by 2030 [5][6].

Core Viewpoint - The article emphasizes the long-term journey of innovation in the pharmaceutical industry, particularly in the hypertension treatment sector, highlighting the recent advancements and unmet needs in this area [3][4]. Group 1: Hypertension Overview - Hypertension affects approximately 1 billion people globally and has seen no significant breakthroughs in core treatment targets for over 40 years [4][5]. - It is a leading cause of cardiovascular diseases and overall mortality, with 10.8 million deaths attributed to high systolic blood pressure in 2019, accounting for about 20% of total deaths [6]. - The prevalence of hypertension is approximately 1.4 billion globally, with 80 million in the U.S. and 90 million in the EU, representing 31% and 24% of the adult population, respectively [6]. Group 2: Treatment Landscape - Current hypertension treatments include lifestyle changes, antihypertensive medications, and some devices [21]. - The article outlines the classification of hypertension into controlled and uncontrolled categories based on blood pressure readings and medication regimens [14]. - The recommended initial medications for hypertension treatment include ACE inhibitors, ARBs, thiazide diuretics, and calcium channel blockers [23]. Group 3: Recent Developments - The recent success of Mineralys in advancing hypertension treatment through innovative drug mechanisms has opened new possibilities in the field [4][5]. - The article discusses the concept of "aldosterone escape," where patients experience a rebound increase in aldosterone levels despite treatment, leading to resistant hypertension [36][39]. - Aldosterone synthase inhibitors (ASI) are highlighted as a promising new class of drugs that can directly inhibit aldosterone production, addressing both RAAS and non-RAAS pathways [40][42]. Group 4: Mechanisms of Hypertension - The pathophysiology of hypertension involves multiple systems, including renal, vascular, neural, and the RAAS system, with obesity also playing a significant role [26][27]. - The article explains the mechanisms by which aldosterone contributes to hypertension, including both direct and indirect pathways [29][36]. Group 5: Clinical Implications - The article emphasizes the importance of accurate blood pressure measurement techniques to avoid misdiagnosis of hypertension, such as white coat hypertension and masked hypertension [18][20]. - It also discusses the need for personalized treatment goals based on individual patient circumstances, particularly for older adults or those with multiple comorbidities [20].